Skip to main navigation

Skip to main content

Prometheus Biosciences Logo Toggle Navigation Menu

Home
Our Story

See Our Story Our Mission
Platform
Pipeline

See Our Pipeline PRA023 PRA052
People

Leadership Board of Directors Scientific Advisors
Careers

Opportunities Benefits
Investors

Overview News Releases Events & Presentations Financials Stock Analysts Governance IR Resources

Events & Presentations

Events & Presentations

Latest Corporate Presentation

Past Events

Oppenheimer 33rd Annual Healthcare Conference

Mar 13, 2023 at 10:40 AM EDT

PRA023 ARTEMIS-UC Presentation: 18th Congress of European Crohn’s and Colitis Organisation (ECCO)

Mar 04, 2023

PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results 758.8 KB

PRA023 APPOLLO-CD Presentation: 18th Congress of European Crohn’s and Colitis Organisation (ECCO)

Mar 03, 2023

The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results 811.5 KB

SVB Securities Global Biopharma Conference

Feb 14, 2023 at 12:00 PM EST

Prometheus Biosciences ARTEMIS-UC and APOLLO-CD Phase 2 Announcement

Dec 07, 2022 at 8:30 AM EST

Prometheus Biosciences ARTEMIS-UC and APOLLO-CD Phase 2 Announcement Presentation 2 MB

R&D Day PR600 Target Unveiling

Jul 26, 2022 at 9:00 AM EDT

R&D Day PR600 Target Unveiling Presentation 6.3 MB

Prometheus Biosciences Phase 1 Data and New Indication Announcement Webcast

Dec 07, 2021 at 8:00 AM EST

Prometheus Biosciences Phase 1 Data and New Indication Announcement Presentation 4.1 MB

Subscribe to our Investor Alerts

Prometheus Biosciences Logo

Copyright © 2023 Prometheus Biosciences. All rights reserved

Contact Us
Terms & Conditions
Privacy Policy
Legal & Compliance
Notice of Privacy Practices
Accessibility Statement
Sitemap

LinkedIn Logo